期刊
ONCOTARGET
卷 8, 期 37, 页码 62780-62792出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19376
关键词
5 '-AMP-activated protein kinase; hepatic fibrosis; hepatic stellate cells; fatty liver diseases; adiponectin
资金
- National Natural Science Foundation of China [81500263, 81600306]
- China Postdoctoral Science Foundation [2016T90973, 2015M572681]
Fibrosis is a common process of excessive extracellular matrix (ECM) accumulation following inflammatory injury. Fibrosis is involved in the pathogenesis of almost all liver diseases for which there is no effective treatment. 5'-AMP-activated protein kinase (AMPK) is a cellular energy sensor that can ameliorate the process of hepatic fibrogenesis. Given the existing evidence, we first introduce the basic background of AMPK and hepatic fibrosis and the actions of AMPK in hepatic fibrosis. Second, we discuss the three phases of hepatic fibrosis and potential drugs that target AMPK. Third, we analyze possible anti-fibrosis mechanisms and other benefits of AMPK on the liver. Finally, we summarize and briefly explain the current objections to targeting AMPK. This review may aid clinical and basic research on AMPK, which may be a novel drug candidate for hepatic fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据